LIFE
aTyr PharmaNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 21, 12:41 PM
    | Mon, Nov. 21, 12:41 PM
  • Mon, Nov. 21, 11:03 AM
    • aTyr Pharma (LIFE -9.3%) closes a $20M term loan facility with Silicon Valley Bank (SVB). The first tranche of $10M was funded on last Friday. Two additional tranches of $5M each may be drawn down later subject to conditions.
    • In connection with the loan, the company issues warrants to SVB to purchase common shares equal to 3% of the loan value.
    • A portion ($2.6M) of the $10M tranche was used to repay the balance of a prior loan with SVB.
    | Mon, Nov. 21, 11:03 AM
  • Mon, Nov. 14, 7:38 AM
    | Mon, Nov. 14, 7:38 AM
  • Mon, Oct. 24, 9:35 AM
    • The FDA designates aTyr Pharma's (NASDAQ:LIFE) Resolaris for Fast Track review for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic disorder characterized by muscle weakness and wasting. It affects ~19K Americans. There are no approved treatments for the condition.
    • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the Biologics License Application (BLA).
    • The company expects to report results from three Phase 1b/2 studies in December.
    | Mon, Oct. 24, 9:35 AM
  • Mon, Oct. 24, 9:15 AM
    | Mon, Oct. 24, 9:15 AM
  • Wed, Aug. 10, 4:26 PM
    • aTyr Pharma (NASDAQ:LIFE): Q2 EPS of -$0.65 beats by $0.06.
    • Cash, cash equivalents and investments of $96.58M.
    • Press Release
    | Wed, Aug. 10, 4:26 PM
  • Wed, May 11, 4:17 PM
    • aTyr Pharma (NASDAQ:LIFE): Q1 EPS of -$0.68 beats by $0.06.
    • Cash, cash equivalents and investments of $111.6M.
    | Wed, May 11, 4:17 PM | 2 Comments
  • Fri, Apr. 8, 5:40 PM
    | Fri, Apr. 8, 5:40 PM
  • Fri, Apr. 1, 11:25 AM
    • Cepheid (CPHD +6%) upgraded to Buy from Neutral by BTIG Research. Price target set at $42 (19% upside).
    • Cardiovascular Systems (CSII +28.1%) upgraded to Buy from Underperform by Needham. Price target set at $16 (20% upside).
    • United Health Services (UHS -0.6%) upgraded to Outperform from Market Perform by Wells Fargo.
    • PRA Health Services (PRAH +1.4%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $51 (17% upside) from $47.
    • Dimension Therapeutics (DMTX +3.1%) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $10 (25% upside) from $12.
    • Novartis (NVS -2%) downgraded to Neutral from Buy by UBS. Price target lowered to CHF72 (3% upside) from CHF100. Downgraded to Neutral from Buy by Citigroup.
    • Intuitive Surgical (ISRG -0.2%) downgraded to Neutral from Buy by BTIG Research.
    • ATyr Pharma (LIFE -1%) downgraded to Market Perform from Outperform by William Blair. Price target lowered to $8 (106% upside) from $42.
    • Achaogen (AKAO -1.4%) downgraded to Market Perform from Outperform by Cowen & Co.
    • Portola Pharmaceuticals (PTLA +4.1%) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $30 (40% upside) from $65.
    • Quintiles Transnational Holdings (Q +1.9%) downgraded to Neutral from Buy by SunTrust Robinson Humphrey.
    | Fri, Apr. 1, 11:25 AM | 1 Comment
  • Thu, Mar. 31, 12:46 PM
    | Thu, Mar. 31, 12:46 PM
  • Thu, Mar. 31, 10:05 AM
    • aTyr Pharma (LIFE -18.9%) Q4 results: Revenues: $0; R&D Expense: $12.7M (+195.3%); SG&A: $3.8M (+123.5%); Net Loss: ($16.5M) (-175.0%); Loss Per Share: ($0.70) (+90.1%).
    • FY2015 results: Revenues: $0; R&D Expense: $34.5M (+105.4%); SG&A: $13.1M (+92.6%); Net Loss: ($48M) (-93.5%); Loss Per Share: ($3.03) (+89.8%); Quick Assets: $125.3M (+688.1%).
    • No guidance given.
    | Thu, Mar. 31, 10:05 AM
  • Wed, Mar. 30, 5:11 PM
    • aTyr Pharma (NASDAQ:LIFE): Q4 EPS of -$0.70 misses by $0.16.
    • Shares +15.2% AH.
    | Wed, Mar. 30, 5:11 PM
  • Wed, Mar. 30, 4:18 PM
    • ATyr Pharma (NASDAQ:LIFE) appoints Sanjay Shukla, M.D., M.S., as Chief Medical Officer. He joints the firm from Novartis where he was VP and Global Head of Integrated Medical Services.
    | Wed, Mar. 30, 4:18 PM
  • Wed, Jan. 6, 5:12 PM
    • Sanuj Ravindran, M.D., joins aTyr Pharma (NASDAQ:LIFE) as Chief Business Officer, responsible for corporate development and strategy. Previously, he was SVP and Global Head, Corporate Development at The Medicines Company.
    | Wed, Jan. 6, 5:12 PM | 1 Comment
  • Dec. 16, 2015, 10:01 AM
    • The Nasdaq Biotechnology Index (NBI) will add aTyr Pharma (LIFE -4.7%) effective at the open Monday, December 21.
    • The index is calculated under a modified capitalization-weighted scheme and re-ranked once per year.
    | Dec. 16, 2015, 10:01 AM
  • Nov. 10, 2015, 4:42 PM
    • aTyr Pharma (NASDAQ:LIFE): Q3 EPS of -$0.48
    | Nov. 10, 2015, 4:42 PM